Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

NanoString DNA data for CNV Analysis

ABSTRACT: Quantification of DNA obtained from prostate cancer tissues and matched blood normals using the NanoString Cancer CN Panel Assay

ORGANISM(S): Homo sapiens

PROVIDER: GSE99355 | GEO | 2017/05/27

SECONDARY ACCESSION(S): PRJNA388192

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Diagnostic and prognostic utility of a unique epigenetic prognostic PHYMA signature in prostate cancer

Project description:Genome wide DNA methylation profiling of normal and Prostate cancer samples. The Illumina GoldenGate Methylation Cancer Panel I with 1,505 CpG sites selected from 807 genes was used to obtain DNA methylation profiles. Samples included 24 normals and 87 tumors.

2014-03-13 | GSE39603 | GEO

RNA profiling from prostate FFPE specimens (Nanostring)

Project description:To study feasibility of gene expression profiling from FFPE tissues using NanoString nCounter platform, we designed a pilot study utilizing samples from prostate cancer cohort. We selected samples from large-scale epidemiologic studies and clinical trials representative of a wide variety of fixation times, block ages and block storage conditions. five paired tumor and adjacent normal prostate tissue speciemens with technical replicates

2014-07-01 | E-GEOD-55055 | biostudies-arrayexpress

Comparison of Nanostring nCounter data on FFPE colon cancer samples and Affymetrix microarray data on matched frozen tissues

Project description:The prognosis of colorectal cancer (CRC) stage II and III patients is still a challenge due to the difficulties of finding robust biomarkers and assays. The majority of published gene signatures of CRC have been generated on frozen colorectal tissues. Because collection of fresh frozen tissues is not routine and the quantity and quality of RNA derived from formalin-fixed paraffin-embedded (FFPE) tissues is vastly inferior to that derived from fresh frozen tissue, a clinical test for improving staging of colon cancer will need to be designed for FFPE tissues in order to be widely applicable. We have designed a custom Nanostring nCounter assay for quantitative assessment of expression of 414 gene elements consisting of multiple published gene signatures for colon cancer prognosis, and systematically compared the gene expression quantification between nCounter data from FFPE and Affymetrix microarray array data from matched frozen tissues using 414 genes. For microarray studies, representative sections of fresh tissue specimens were flash frozen in liquid nitrogen and stored at â80Â°C until RNA isolation. RNA was purified from tissue sections containing >80% epithelial tumor tissue using RNeasy (QIAGEN, Valencia, CA) according to manufacturerâs instructions. Samples were hybridized to Affymetrix arrays Human Genome U133 Plus 2.0 GeneChip Expression Arrays, Santa Clara, CA). The samples included four healthy control patient tissues, 12 stage I, 17 stage II, 20 stage III and 15 stage IV CRC patient tissues. Please note that only the *matched.csv files containing matched 414 genes' microarray and nanostring data are provided without the nanostring experimental descriptions. The matching samples between GSE62932 and the Nanostring study are indicated in the matching_samples.txt.

2015-10-27 | E-GEOD-62932 | biostudies-arrayexpress

Nanostring Cancer Immune Panel Pre and Post ETC-159

Project description:Nanostring Cancer Immune Panel Pre and Post ETC-159

| PRJNA702774 | ENA

Nanostring ncounter NHP Immunology V2 panel

Project description:Nanostring ncounter NHP Immunology V2 panel

| PRJNA792145 | ENA

nCounter NanoString Human Immunology V2 panel

Project description:nCounter NanoString Human Immunology V2 panel

| PRJNA751396 | ENA

Profiling of Cell cycle genes dysregulated by knockdown of lncRNAs using Nanostring Gene Expression Assay

Project description:Idetification of cell cycle-related genes dysregulated by knockdown of MYCLos (lncRNAs) in colorectal cancer-derived HCT116 and in prostate cancer-derived PC3 Using siRNAs targeting MYCLos, the cells were transfected and RNA samples from the treated cells were subjected to Nanostring Gene Expression Assay

2012-07-03 | E-GEOD-39077 | biostudies-arrayexpress

NanoStringNormCNV: pre-processing of NanoString CNV data.

Project description: Not available

| S-EPMC5860631 | biostudies-literature

Diagnostic and prognostic utility of a unique epigenetic prognostic PHYMA signature in prostate cancer

2014-03-13 | E-GEOD-39603 | biostudies-arrayexpress

Whole genome characterisation of chemoresistant ovarian cancer [NanoString miRNA]

Project description:Patients with high-grade serous ovarian cancer (HGSC) have experienced little improvement in overall survival, and standard treatment has not advanced beyond platinum-based combination chemotherapy, during the past 30 years. To understand the drivers of clinical phenotypes better, here we use whole-genome sequencing of tumour and germline DNA samples from 92 patients with primary refractory, resistant, sensitive and matched acquired resistant disease. We show that gene breakage commonly inactivates the tumour suppressors RB1, NF1, RAD51B and PTEN in HGSC, and contributes to acquired chemotherapy resistance. CCNE1 amplification was common in primary resistant and refractory disease. We observed several molecular events associated with acquired resistance, including multiple independent reversions of germline BRCA1 or BRCA2 mutations in individual patients, loss of BRCA1 promoter methylation, an alteration in molecular subtype, and recurrent promoter fusion associated with overexpression of the drug efflux pump MDR1. Total RNA was hybridised to NanoString miRNA Human v2.1 probes, immobilized to NanoString cartridge and analysed on the NanoString Digital Analyzer. NanoString nSolver Analysis Software was utilised to check QC metrics and extract raw miRNA counts. Expression was normalised for input using the housekeeping genes. Contributor: The Australian Ovarian Cancer Study Group

2015-05-19 | E-GEOD-65819 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data